HDAC在心脏病理性重构中的调控机制及意义——“精准医学”模式下的潜在干预靶点  

Mechanism of histone deacetylases in regulation of cardiac pathological remodeling: potential therapeutic target under precision medicine

作　　者：李一飞[1] 华益民[1] 周开宇[1] 

机构地区：[1]四川大学华西第二医院儿童心血管科妇儿疾病与出生缺陷教育部重点实验室,四川成都610041

出　　处：《心脏杂志》2017年第5期586-591,共6页Chinese Heart Journal

基　　金：国家自然科学基金项目资助(81270226;81570369;81571515);长江学者和创新团队发展计划项目资助(IRT0935)

摘　　要：心力衰竭(HF)是多种心血管疾病的最终临床转归,其中心脏病理性重构是HF重要的病理生理基础。目前尚缺乏针对心脏病理性重构的特异性治疗手段,因此目前对于HF的治疗尚无法从本质上改变其生物学特性。组蛋白去乙酰化酶(HDACs)作为一种重要的表观遗传调控机制,已经被证实参与调控多条心脏病理性进程通路。同时多种针对特定HDACs的靶向干预药物已经面试,这为HF的治疗提供了全新的视角和思路。本文将对HDACs在心脏病理性重构中的意义及潜在靶向干预靶点进行综述。Heart failure is the terminated stage of most kinds of cardiovascular diseases and the cardiac pathological remodeling is the most essential part during such pathophysiological procedure. At present, there is still no specific therapy for heart failure, targeting its biological changes. Histone deacetylases （HDACs） have been proved to be involved in several regulation pathways in pathological process, one important epigenetic mechanism. Moreover, several kinds of targeted medications for specific HDACs have been developed, which provides new insights in treatment of heart failure. In this article, we will summary the functions and regulatory roles of HDACs in cardiac pathological procedure and their potential therapeutic targets.

关 键 词：组蛋白去乙酰化酶 心力衰竭 病理性重构 精准医学 

分 类 号：Q556.9[生物学—生物化学]